Ann: Imugene Presentation to Bell Potter Conference, page-58

It's strange watching the cycles of the market.

I am invested in DXB (Have been for over 5 years) - when it was 0.07c not that long ago, I added heavily to my position knowing very well the fundamentals had not changed it was just DXB didn't have the appeal (yet)... Fast forward to today and its at 0.45c, with their interim read out data showing the trial progressing well and a couple of licensing deals being inked, now..it's starting to get some appeal.

But here sits IMU, trading an enterprise value not that far away from DXB but with a significantly larger pipeline and key catalysts in the not too distant future. Seeing this at at the current price, important to always remember with Biotechs, patience and timing entry is key. IMO this has been oversold significantly due to timing on catalysts and FY month end timing.

Here is my Biotech strategy investing:
1. July - May: Research as much as you can about the best opportunities and fundamentals.
2. June: Go shopping build positions.
3. Wait.